Table 2.
Ethical domains of practical considerations in xenotransplantation
| Ethical domains | |||||||
|---|---|---|---|---|---|---|---|
| Autonomy | Religious taboos against pigs | Racial and ethnic attitudes | Extent of informed consent | Trans-species infection; chimerism | Tracking infection risk | Stigma of having a pig kidney | |
| Equity | Who will be in clinical trials | Who will be eligible for xenotransplant | Availability to groups excluded from transplant now | Insurance coverage public and private | Insurance coverage public and private | Number of kidneys needed per transplant | |
| Utility | Oversight national, local; need for rules to conform | Cost of program infrastructure and transplants | Potential savings from xenotransplant over allotransplant | Return on investment to commercial entities involved | Concern for monopoly pricing if limited number of providers | Hyperacute rejection | Pig kidney response to human hormones |
| Xenotransplant regulatory oversight | Approval of genetic changes | Need for more animal models before human trials | Allocation of pig kidneys | Tracking pig kidney success | Tracking infection risk | ||
| Justice | Violate the laws of nature; cruelty to animals | Lopsided distribution of healthcare spending | Diversion of money away from primary care | Who will be in clinical trials | Who will be eligible for xenotransplant | How to prevent hierarchy of kidneys and of recipients | |
| Availability to groups excluded from transplant now | Will government cover cost of immuno- suppression medications | ||||||